Navigation Links
Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting
Date:9/15/2009

CRANBURY, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.

The poster presents data from a Phase 2A study of PL-3994 in controlled hypertensive volunteers who were taking antihypertensive medications and otherwise healthy. The study is preparatory to planned future trials, in which heart failure patients will receive daily subcutaneous injections of PL-3994 with the objective of reducing the re-hospitalization rate in heart failure patients after an acutely decompensating event.

"This study supports our hypothesis that PL-3994 can safely be administered to patients receiving antihypertensive medications, such as heart failure patients," said Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin. "We are excited by the potential for PL-3994, which is the only reported natriuretic peptide drug being developed for daily, subcutaneous, self-administration by heart failure patients."

Key Results

PL-3994 was administered by subcutaneous injection to volunteers with controlled hypertension, with key results including:

  • Increases in plasma concentrations of cyclic guanosine monophosphate (cGMP) levels, a pharmacological response consistent with the effects of endogenous natriuretic peptides on cardiovascular function, similar to results seen in an earlier Phase 1 study.
  • A maximum tolerated dose of 0.3 micrograms per kilogram, based upon a pre-specified decrease in blood pressure.
  • PL-3994 was well tolerated, with no serious adverse events observed in the study population.

About PL-3994

PL-3994 is a natriuretic peptide-A receptor agonist compound developed by Palatin Technologies for treatment of heart failure. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. PL-3994 is being developed as a subcutaneously administered drug, and is well absorbed through this route of administration.

Commercial Opportunity

PL-3994 is being developed for daily subcutaneous self-administration by heart failure patients to decrease re-hospitalization rates for heart failure. Heart failure affects over 5.7 million people in the United States, with 670,000 new cases diagnosed each year. Despite the treatment of heart failure with multiple drugs, the prognosis remains poor. There were over 1.1 million hospitalizations for heart failure in 2006 in the United States, with projected direct and indirect costs of heart failure in the United States for 2009 of $37.2 billion.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
3. Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
4. Palatin Technologies to Present at Cowen Annual Health Care Conference on March 19, 2009
5. Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009
6. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
7. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
8. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
9. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
10. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
11. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... 2017 , ... Maryland’s soybean farmers have improved the sustainability ... the United Soybean Board. , Thanks to the responsible use of technology ... on less land per bushel, the report says. The United Soybean Board’s “Soy ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing ... Cotey, with or without a referral. Dr. Cotey is a trusted dentist who has ... tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to ...
(Date:6/25/2017)... ... ... CareSet Labs released the Root NPI Graph today at the 2017 Academy ... of the Doctor Referral teaming dataset commonly available from Medicare. , Originally created through ... “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by Trotter, the ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman ... Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency ... the dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... CHICAGO , June 19, 2017  Hill-Rom Holdings, Inc. ... conference call and webcast on Friday, July 28, 2017, beginning ... Conference Call Audio Only Dial-in information: To participate in the ... Please dial into the call at least 10 minutes prior ... Code is 34090339.  ...
(Date:6/16/2017)... -- Datascope Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic ... code.     ... NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to any System ...
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a medical ... of intravenous (IV) therapy, is pleased to announce it ... of Nonsurgical Hospital Supplies and Equipment at the 2017 ... for the medtech industry. The award was presented by ... K. Javits Center in New York ...
Breaking Medicine Technology: